Abstract
Early studies showed dramatic improvement in some depressed patients when a brief course of parenteral reserpine was added to ineffective tricyclic antidepressant (TCA) treatment. We treated eight patients with DSM-III melancholic major depression with desipramine (DMI)≥2.5 mg/kg/day (plasma levels>125 ng/ml) for at least 4 weeks. All patients failed to respond and received reserpine 5 mg IM b.i.d. over 2 days, in seven cases as a placebo-controlled, double-blind trial. One patient had dramatic resolution of depressive and psychotic symptoms within 48 h, but relapsed within 2 weeks; two other patients had transient hypomanic symptoms. Depression ratings did not significantly change for the sample as a whole, but plasma and cerebrospinal fluid (CSF) levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) decreased and CSF levels of homovanillic acid (HVA) and 5-hydroxy-indoleacetic acid (5-HIAA) increased. Despite robust effects on central monoamine metabolism, reserpine augmentation appears insufficiently effective for routine use in managing refractory depression.
Similar content being viewed by others
References
American Psychiatric Association Committee on Nomenclature and Statistics (1980) Diagnostic and statistical manual on mental disorders, 3rd edn. Washington, DC, American Psychiatric Association
Amsterdam JD, Berwish N (1987) Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharm (in press)
Asberg M, Bertilsson L, Martensson B, Scalia-Tomba G-P, Thoren P, Traskman-Bendz L (1984) CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69:201–219
Ayd FJ, Jr (1958) Drug-induced depression — Fact or fallacy. NY State J Med 58:354–356
Ayd FJ, Jr (1985) Reserpine therapy for tricyclic-resistant depressions. Int Drug Ther Newslett 20:17–18
Baraban JM, Wang RY, Aghajanian GK (1978) Reserpine suppression of dorsal raphe neuronal firing: Mediation by adrenergic system. Eur J Pharmacol 52:27–36
Barsa JA, Kline NS (1955) Treatment of two hundred disturbed psychotics with reserpine. JAMA 158:1101–1113
Barsa JA, Kline NS (1956) Use of reserpine in disturbed psychotic patients. Am J Psychiatry 112:684–691
Bertilsson L, Asberg M, Lantho O, Scalia-Tomba GP, Traskman-Bendz L, Tybring G (1982) Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls. Psychiatr Res 6:77–83
Brodie BB, Bickel MH, Sulser F (1961) Desmethylimipramine, a new type of antidepressant drug. Med Exp 5:454–458
Carlsson A, Dahlstrom A, Fuxe K, Hillary N-A (1965) Failure of reserpine to deplete noradrenaline neurons of α-methylnoradrenaline formed from α-methyl DOPA. Acta Pharmacol Toxicol 22:270–276
Carney MWP, Thakurdas H, Sebastian J (1969) Effects of imipramine and reserpine in depression. Psychopharmacologia 14:349–350
Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment: Implications for the etiology and therapy of depression. Arch Gen Psychiatry 38:1160–1180
Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751–763
Cuomo V, Cagiano R, Brunello N, Fumagalli R, Racagni G (1983) Behavioural changes after acute and chronic administration of typical and atypical antidepressants in rats: Interactions with reserpine. Neurosci Lett 40:315–319
deKirmenjian H, Maas JW (1974) MHPG in plasma. Clin Chim Acta 52:203–208
de Montigny C, Grunberg F, Mayer A, Deschenes J-P (1981) Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 138:252–256
Flach FF (1955) Clinical effectiveness of reserpine. Ann NY Acad Sci 61:161–166
Forsman A, Dahlstrom A, Wahlstrom J, Wendestam C, Akesson HO (1983) Reserpine treatment of certain depressive conditions: Case report, treatment, and possible mechanisms of action. Curr Ther Res 34:991–998
Friedman E, Dallob A, Levine G (1979) The effect of long-term lithium treatment on reserpine-induced supersensitivity in dopaminergic and serotonergic transmission. Life Sci 25:1263–1266
Gahagan LH (1957) Ineffectiveness of chlorpromazine and rauwolfia serpentina preparations in the treatment of depression. Dis Nerv Syst 18:390–393
Garattini S, Giachetti A, Jori A, Pieri L, Valzelli L (1962) Effect of imipramine, amitriptyline and their monomethyl derivatives on reserpine activity. J Pharm Pharmacol 14:509–514
Giachetti A, Shore PA (1966) Studies in vitro of amine uptake mechanisms in heart. Biochem Pharmacol 15:607–614
Goodwin FK, Ebert MH, Bunney WE Jr (1972) Mental effects of reserpine in man: A review. In: Shader RI (ed) Psychiatric complications of medical drugs. Raven, New York, pp 73–101
Haskovec L, Rysanek K (1967) The action of reserpine in imipramine-resistant depressive patients. Psychopharmacologia 11:18–30
Hays WL (1973) Statistics for the social sciences. Holt, Rinehart and Winston, New York
Heninger GR, French NY, Slavinsky AT, Davis L, Mueller PS (1970) A short clinical rating scale for use by nursing personnel, II: Reliability, validity, and application. Arch Gen Psychiatry 23:241–248
Heninger GR, Charney DS, Sternberg DE (1983) Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 40:1335–1342
Hopkinson G, Kenny F (1975) Treatment with reserpine of patients resistant to tricyclic antidepressants: A double-blind trial. Psychiatr Clin 8:109–114
Kinross-Wright V (1955) Chlorpromazine and reserpine in the treatment of psychoses. Ann NY Acad Sci 61:174–182
Kirk L, Gram LF, Jensen PS (1970) Clinical experience with 10 mg reserpin injected I.M. in depressive disorders. Acta Psychiatr Scand 217 (Suppl):55–56
Levin BE (1984) Retrograde axonal transport, of β-adrenoreceptors in rat brain: Effect of reserpine. Brain Res 300:103–112
Maas JW, Hattox SE, Landis DH, Roth RH (1976) The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Brain Res 118:167–173
Maggs R, Ellison RM (1960) Five-year follow-up of results of reserpine therapy in mental hospital practice. J Ment Sci 106:590–598
Maj J, Rogoz Z, Skuza G, Sowinska H (1983) Reserpine-induced locomotor stimulation in mice chronically treated with typical and atypical antidepressants. Eur J Pharmacol 87:469–474
Mazure C, Nelson JC, Price LH (1986) Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 43:451–456
Nelson JC, Jatlow P, Quinlan DM, Bowers MB (1982) Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry 39:1419–1422
Pettibone DJ, Totaro JA, Pflueger AB (1984) Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants. Eur J Pharmacol 102:425–430
Pocock SJ (1983) Clinical trials: A practical approach. Wiley, Chichester
Poldinger W (1959) Diskussionsbemerkung an der 129. Versammlung der Schweiz. Ges. für Psychiatrie. Schweiz Arch Neurol Psychiatr 84:327
Poldinger W (1963) Combined administration of desipramine and reserpine of tetrabenazine in depressive patients. Psychopharmacologia 4:308–310
Price LH, Charney DS, Heninger GR (1986) Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143:1387–1392
Racagni G, Mocchetti I, Renna G, Cuomo V (1982) In vivo studies on central noradrenergic synaptic mechanisms after acute and chronic antidepressant drug treatment: Biochemical and behavioral comparison. J Pharmacol Exp Ther 223:227–234
Shore PA, Giachetti A (1978) Reserpine: Basic and clinical pharmacology. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, Vol. 10, Neuroleptics and schizophrenia. Plenum, New York, pp 197–218
Sugrue MF (1983) Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 21:1–33
Sulser F, Soroko F (1965) On the role of rate of brain norepinephrine release in the antibenzoquinolizine action of desipramine. Psychopharmacologia 8:191–200
Tourney G, Isberg EM, Gottlieb JS (1955) The use of reserpine in an acute psychiatric treatment setting. AMA Arch Neurol Psychiatry 74:325–328
Weiner N (1970) Regulation of norepinephrine biosynthesis. Annu Rev Pharmacol 10:273–290
Zivkovic B, Guidotti A, Costa E (1973) Increase of tryptophan hydroxylase activity elicited by reserpine. Brain Res 57:522–526
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Price, L.H., Charney, D.S. & Heninger, G.R. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology 92, 431–437 (1987). https://doi.org/10.1007/BF00176473
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00176473